Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERIDIAN: AZD2936 in Locoregionally-Advanced High Risk HNSCC
NCT05414032Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Jul 2023
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rilvegostomig in head and neck squamous cell carcinoma (HNSCC), sponsored by University Health Network. Started Jul 2023; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05414032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414032.